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LETTER TO THE EDITOR
P-values, survival analyses and phase II trials
Sir - The paper on chemotherapy of salivary gland tumours
by Jones et al. (1993), recently published in BJC, is very
misleading. In particular, the author's comparisons of sur-
vival are of dubious value and show a complete misunder-
standing of the role of P-values in the context of a phase II
trial which was terminated after the first phase. Also, while it
was commendable to use randomisation in a phase II trial,
the early termination means that in the event the randomisa-
tion (of 16 patients) became worthless, contrary to the im-
pression given in this paper.
The authors report a median survival of 243 days under
one treatment arm, as compared with 450 days in the other
group. This is an astonishingly large difference, being almost
a doubling of the survival time, from 8 months to 15 months.
Few chemotherapy trials would hope to observe so striking a
difference in survival. What is the reason, therefore, for the
authors (correctly) declaring this difference to be not
significant? Simply that their sample size was so small (16
patients) that any conceivable difference that they might have
observed would inevitably be found 'not significant'. A
P-value in such a context has no meaning, and is not worth
calculating. All the P-value tells us is that, given such a small
study, the observed difference may well be due to chance.
The 'not significant' P-value does not indicate that there is
unlikely to be any difference between the treatments - in fact,
all we can tell from it is that the study was small.
It would have been interesting to have been presented with
the relevant sample size calculations. The authors should
have indicated what size difference in survival they antici-
pated as being realistic. They could then have estimated how
many patients would be required in order to have a reason-
able chance of detecting their hypothesised difference; one
suspects that perhaps ten times as many patients would have
been more appropriate.
What methods of analyses are suitable? The authors, if
they dared, could have presented confidence intervals for the
survival rates. These confidence intervals would have been
extremely wide and overlapping, telling the reader that the
observed estimates of median survival are so imprecise as to
be of little value.
Much of the problem over sample size arises because a
two-stage 'Gehan design' phase II trial was used. Such a
study is used for screening new agents for response. Let us
assume that the new treatment is effective and will on
average produce a response in 20% of patients or more.
Then the first stage of the trial is designed so that there will
be a high probability ofcontinuing the study to completion if
the true response rate is at least 20%; in particular, if no
responses are observed in the first 14 patients, it is most
likely that the true response rate could be 20% and so the
study can be safely abandoned. That is what happened in
this case. Thus the authors are entitled to conclude that the
true response rate is unlikely to be 20% or more. But that is
all they can conclude.
Their sins were then to proceed to make subgroup com-
parisons of the two chemotherapy regimens, and to proclaim
that this was a randomised trial comparing epirubicin+ 5-FU
with cisplatinum. Yes, it was a randomised trial, but the
early termination has made the randomised comparison
worthless, totally misleading and barely worth reporting.
The authors cite Herson (1984) as a reference for Gehan
phase II trials; Herson does indeed devote half a page to this
design. What a pity the authors failed to read that half page
to the end. As Herson wrote: 'Unfortunately, Gehan's rule
has been greatly misunderstood by clinicians. Most believe
that the rule is a hypothesis-testing procedure and that, for
00 = 0.20, 14 patients is sufficient for a clinical trial. Rarely is
the second sample mentioned.'
Clearly a statistican was not involved in the analysis of this
trial, nor could the paper have been refereed by a statistician.
Yours etc,
P. Fayers
MRC Cancer Trials Office,
5 Shaftesbury Road,
Cambridge CB2 2BW.
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